Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > May 13, 2024
Daily News
May 13, 2024
- Lilly’s Gemzar to Exit Japan Market Next Spring under G1 Withdrawal Rule
May 13, 2024
- Simplified Delisting to Be Allowed for Generics with Low Market Share from September: MHLW
May 13, 2024
- Posaconazole Added to List of Azole Antifungals Contraindicated for Xarelto on Bleeding Risks
May 13, 2024
- Sumitomo Splits Non-Pharma “Frontier” Business
May 13, 2024
- Shionogi COVID Jab Up for PAFSC Review Again after Efficacy Questions; Pfizer’s Zavicefta and Lots More on Roster
May 13, 2024
- Shionogi Nabs Global Rights to Maze’s Pompe Disease Therapy
May 13, 2024
- Amgen Files Otezla for Palmoplantar Pustulosis in Japan
May 13, 2024
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…